Erasca's $550M offering; Summit sells an antibiotic

July 14, 2026 11:09 AM EDT News Briefing Eras­ca's $550M of­fer­ing; Sum­mit sells an an­tibi­ot­ic ENDPOINTS Plus, news about sub­cu­ta­neous Leqem­bi, WuXi AppTec and Q32 Bio. 📊 Eras­ca tar­gets $550M for KRAS drugs: The biotech’s pub­lic of­fer­ing … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER